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One third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, representing a huge reservoir
of potential tuberculosis (TB) disease. Risk of progression to active TB is highest in those with HIV coinfection. However, the
nature of the host-pathogen relationship in those with “latent TB infection” and how this is aﬀected by HIV coinfection are poorly
understood. The traditional paradigm that distinguishes latent infection from active TB as distinct compartmentalised states is
overly simplistic. Instead the host-pathogen relationship in “latent TB infection” is likely to represent a spectrum of immune
responses, mycobacterial metabolic activity, and bacillary numbers. We propose that the impact of HIV infection might better
be conceptualised as a shift of the spectrum towards poor immune control, higher mycobacterial metabolic activity, and greater
organism load, with subsequent increased risk of progression to active disease. Here we discuss the evidence for such a model and
the implications for interventions to control the HIV-associated TB epidemic.
1. Introduction
Tuberculosis (TB) remains a major challenge to global public
health in the 21st century [1]. In 2008, there were estimated
9.4 million incident cases and 11.1 million prevalent cases
[2]. These resulted in 1.3 million TB deaths in HIV-
negative individuals and additional 0.5 million deaths in
HIV-infected individuals. This immense burden of disease is
fuelled by very high rates of infection with Mycobacterium
tuberculosis, estimated to occur in approximately one third
of the world’s population [3]. With current rates of progress,
the millennium development goal (MDG) and associated
World Health Organization (WHO) Stop TB targets for TB
control will not be achieved by 2015 [4].
The failure to control TB in modern times stems,
at least in part, from complacency towards TB control
in the 1970s and 1980s and the subsequent devastating
impact of the HIV-1 pandemic and may be further shaped
by other important emerging epidemiological factors at a
global level [1, 5]. Progress has also been hindered by the
limited progress in developing more eﬀective tools such
as point-of-care diagnostics and treatments for active and
latent disease, preventive vaccines, and laboratory assays of
immune protection and cure. This lack of progress is, in
turn, related to a poor understanding of the fundamental
relationship between M. tuberculosis and the human host
and especially the nature of what is referred to as “latent
tuberculosis infection”.
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Table 1: Evidence that suggests the existing view of “latent tuberculosis infection” and active tuberculosis disease as binary compartmen-
talised states is oversimplistic.
(1) Risk of developing active tuberculosis in patients with “latent tuberculosis Infection” varies considerably over time, suggesting
that “latent” infection is a heterogeneous state
(2) Isoniazid is active against actively replicating organisms and yet reduces TB risk in those with “latent tuberculosis infection”
(3) Isoniazid preventive therapy entails 6−12 months of therapy for good eﬃcacy, possibly suggesting the pool of “latent”
mycobacteria cycle through phases of metabolic activity and replication over time
(4) A significant proportion of patients with microbiologically proven pulmonary tuberculosis identified by prevalence surveys have
no symptoms
(5) Serological markers are predictive of patients with diﬀerent stages of tuberculosis infection and disease, including those with
asymptomatic active disease
(6) Mycobacterial lesions within tissues from the same individual may represent a wide spectrum, ranging from sterility to
multibacillary disease
(7) Discordance between tuberculin skin test and interferon-gamma release assay results cannot simply be explained by diﬀerences
in specificity. These assays appear to reflect diﬀerent aspects of immune sensitization which are as yet incompletely understood.
AlthoughM. tuberculosiswas described as the aetiological
agent of TB in 1882, fundamental insights into TB infection
and disease have altered little for many decades. By analogy,
the contrast between TB and HIV is stark. HIV is a relatively
new pathogen discovered less than 30 years ago, and yet
rapid advances in understanding pathogenesis were made
quickly. HIV transmission is well understood and diagnosis
is rapid, cheap, and reliable. There are quantitative tests of
both HIV load and the impact on the host immune system,
which have strong prognostic significance. Completely new
treatments have been developed and have transformed
prognosis.
A pivotal advance in addressing the HIV/AIDS epidemic
was made in the mid-1990s when our understanding of
the host-pathogen relationship completely altered. Prior to
this time, HIV-infected patients were classified as having
a clinically “latent” phase lasting many years between the
seroconversion and the later symptomatic phase. It was
generally assumed that the virus was similarly quiescent
during this asymptomatic phase. However, advances in
molecular techniques that permitted direct measurements
of plasma HIV-1 load and CD4 lymphocyte counts and the
advent of combination antiretroviral drug therapy resulted in
a complete paradigm shift. “Clinically latent” HIV infection
was discovered to be characterised by phenomenally high
rates of virion replication and CD4 cell turnover [6, 7].
This observation has been fundamental to our approach to
treatment and prevention.
Traditional views of “latent TB infection” are also being
questioned. However, the laboratory tools with which to
study this still lag considerably behind those of the HIV
research field and obtaining samples from sites of disease
is more challenging. In this paper we discuss the changing
paradigm of infection and disease and draw on clinical and
epidemiological observations to consider how this may be
especially important to understanding the disease spectrum
in those living with HIV infection. We further discuss the
implications of this changing view to approaches for control
of the HIV-associated TB epidemic.
2. “Latent” Tuberculosis Infection
2.1. The Conventional Paradigm. The conventional view
recognises TB infection and TB disease in human subjects
as distinct binary states. Transitions between these states
are described as resulting in one of three main clinical
outcomes—“primary TB disease”, “latent TB infection” and
“reactivation or post-primary TB disease.” In a minority of
subjects (especially children), initial immune containment
fails and infection progresses usually within 1-2 years to
disease (primary TB). In the majority, however, immune
responses control and limit the infection, such that individ-
uals remain free from disease for prolonged periods but have
evidence of infection defined by immunological sensitization
to the organism. Evidence of this state of “latent TB infec-
tion” is therefore provided by positive tuberculin skin test
(TST) responses or interferon-gamma release assays (IGRAs)
incorporating species-specific mycobacterial proteins [8].
A small minority of such individuals will at some stage
during their lifetime develop disease (“reactivation” or “post-
primary TB”), in which loss of control of bacillary replication
leads to development of TB disease.
2.2. Limitations of the Conventional Paradigm. The inade-
quacy of the existing compartmentalised view of TB infection
and disease is apparent from the profusion of confusing
terminologies used in the literature. Such terms include
latent, active, inactive, subclinical, acute, chronic, persistent,
dormant, recent, remote, quiescent, and incipient infection
or disease. Collectively, these suggest that the host-pathogen
relationship might better be considered as a spectrum.
A number of lines of evidence support the notion that
the existing paradigm is an oversimplification (Table 1).
The risk of TB among patients with “latent TB infection”
changes considerably over time, depending strongly on how
recently the infection was acquired [11]. This suggests that
there is heterogeneity over time in the biology of “latent
TB infection”. Evidence of such heterogeneity also comes
from frequently observed discordance between the TST
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Table 2: Proposed framework of potential outcomes of the host-pathogen relationship following exposure to Mycobacterium tuberculosis
infection. (adapted from [9, 10]).
Terminology T cell priming
Mycobacterial
numbers
Symptoms Impact of HIV
infection
Impact of
ART
(1) Infection eliminated by
innate immune system
Innate immune − − −  
(2) Infection eliminated by
acquired immune response
Acquired immune + − −
(3) Infection occurs but
remains under immune
control
Quiescent infection + + −
(4) Active bacterial replication
but remains subclinical
Active infection + + + + −
(5) Uncontrolled bacterial
replication and clinical TB
disease
TB disease + + + + + + ++
responses and IGRA results. These diﬀerences cannot simply
be explained by lower specificity of the TST; a proportion of
patients are IGRA positive but TST negative and others are
IGRA negative but TST positive. Reversion from positive to
negative appears to occur more commonly for IGRAs than
TST responses [9]. This may relate to the fact that IGRAs
tend to record the presence ofM. tuberculosis-specific eﬀector
memory and terminally diﬀerentiated eﬀector memory cells
[12], and the persistence of these cells is thought to require
continued antigen stimulation. In contrast, TST reactions
also contain a proportion of cells of central memory
phenotype [13], whichmay contribute to the development of
positive TST reactions in the absence of long-term infection.
The use of 6−12 months of isoniazid preventive therapy
(IPT) is associated with a TB risk reduction of 60% (95%
CI, 48−69) in HIV-uninfected individuals [14] and may
lead to eventual reversion of TST status, suggesting possible
eradication of infection [15]. Isoniazid acts by inhibiting
mycobacterial cell wall synthesis and is therefore only active
against actively replicating organisms. However, despite the
fact that the number of organisms present is likely to be
much lower than the numbers present in those with active
disease, IPT is eﬀective when given in courses lasting 6−12
months. This suggests that only a proportion of bacilli
in patients with “latent TB infection” are replicating at
any given time. A possible explanation is that “latent” M.
tuberculosis bacilli cycle through a range of metabolic states
over time, cumulatively rendering a large proportion of the
pool of latent organisms susceptible to the drug during 6−12
months of preventive therapy. Thus, what has been referred
to as “latent TB infection” may actually represent a dynamic
balance between the organisms in a range of metabolic states
and variations in immune control.
Data from TB prevalence surveys also indicate that a
rigid binary distinction between “latent TB infection” and
active symptomatic TB disease is oversimplistic. For very
pragmatic reasons, TB control programmes in resource-
limited settings have usually defined pulmonary TB suspects
as those who have been coughing for at least 2-3 weeks
[16]. However, during TB prevalence surveys, culture-proven
TB is diagnosed in a proportion of patients who have
no symptoms of disease at all [17–19]. For example, in a
large survey of bacteriologically confirmed pulmonary TB in
Vietnam, cough for more than 2 weeks was reported by just
55% of patients, cough of any duration was reported by 67%,
and any symptom suggestive of TB was reported by 74% of
patients [19]. Thus, approximately one in four patients was
symptom-free at the time of the survey.
If left untreated, patients with asymptomatic active TB
may progress to develop symptomatic disease over time
as observed among HIV-infected patients in Zimbabwe
[20]. Thus, asymptomatic active TB may be an inter-
mediate disease state between “latent TB infection” and
overt symptomatic disease. This concept is supported by
novel serological assays, which also provide evidence for
a spectrum of disease stages, with patients with clinical
disease and subclinical TB producing antibodies to a range
of diﬀerent stage-specific mycobacterial proteins [21–23].
In those with TB disease, clinical manifestations are also
extremely diverse depending on anatomical site of disease,
bacillary numbers (paucibacillary and multibacillary), and
the host inflammatory response. Even within the same indi-
vidual, diverse lesions ranging from sterility to multibacillary
disease have been observed in a primate model of TB,
suggesting that both “active” and “latent” lesions may coexist
in the same individual [24].
3. Proposed Alternative Paradigm of “Latent”
Tuberculosis Infection
There is now growing support within the field that the
nature of the relationship between M. tuberculosis and the
human host represents a spectrum of immune responses,
mycobacterial metabolic activity, and organism load. In two
viewpoints, Young, Barry, and colleagues have divided this
spectrum into five diﬀerent states that represent a dynamic
spectrum ranging from immunity to TB disease (Table 2)
[9, 10]. Following exposure to M. tuberculosis, infection may
either be eliminated by the innate immune response (without
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Figure 1: A conceptual stylised diagram showing rising total
bacillary load ofMycobacterium tuberculosis over time in an infected
patient. The patient initially retains good immune control and
low bacillary numbers (quiescent infection). Subsequent loss of
immune control is associated with rising bacillary numbers (active
infection) and eventual development of symptoms (TB disease).
The risk of transition from latent infection to active infection
and disease is increased markedly by HIV coinfection whereas
antiretroviral therapy would tend to enhance immune control.
the need for T cell priming) or eliminated following devel-
opment of an acquired immune response. Such states may
be referred to as “innate immune” and “acquired immune”,
respectively (Table 2). Among those who are unable to
prevent or eliminate infection following exposure, a majority
establish and maintain immune control. Such individuals
typically have evidence of T cell priming and maintain
low bacillary numbers (quiescent infection). A subsequent
shift in the host-pathogen response, however, may permit
active mycobacterial replication, leading to subclinical active
infection (Figure 1). The relationship between “quiescent”
and “active” infection is likely to be a dynamic one over time
with bidirectional shifts between the two. Loss of immune
control and escalating mycobacterial load, however, may
subsequently lead to the development of symptoms and overt
clinical disease (Figure 1).
4. Impact of HIV on the Proposed
Host-Pathogen Relationship
4.1. Hypothesis. HIV infection is the most potent risk
factor for the development of TB disease. The existing
understanding of this is that HIV leads to an increased risk
of rapidly progressive primary TB following exposure and
also an increased risk of reactivation of “latent TB infection”
to active disease. However, rather than increasing the risk
of transition between compartmentalised disease states,
we hypothesize that HIV coinfection has a fundamental
impact on the spectrum of the host-pathogen relation-
ship with a general shift towards poor immune control,
high bacillary numbers, and subsequent development of
active infection and symptomatic disease (Figure 1; Table 2).
Recurrent exogenous re-exposure to M. tuberculosis in high
TB prevalence settings is also very likely to play an important
role, further increasing bacillary numbers and increasing the
likelihood of progression to disease. In the remainder of
this paper, we consider evidence for this hypothesis and the
implications for disease control strategies.
4.2. Epidemiological Observations. Although HIV impairs
some aspects of innate immune responses to M. tuberculosis
[25], the impact of risk of acquisition of infection following
exposure is unknown. Studies of intravenous drug abusers in
New York early in theHIV epidemic did not find an increased
risk [26] but the conclusion is undermined by the fact that
assessment of the presence of infection was made using
the tuberculin skin test, which has impaired sensitivity in
those with HIV infection. Other data have shown very high
rates of recurrent TB among HIV-infected individuals due
to reinfection [27], possibly indicating high susceptibility
to reinfection. However, this aspect of the host-pathogen
relationship remains poorly characterised.
Following acquisition of HIV-1 infection, the risk of
TB in individuals with M. tuberculosis infection increases
from an approximately 10% lifetime risk to over 10% each
year [5]. The risk in those living with HIV depends on the
degree of immunodeficiency, the prevailing socioeconomic
conditions, and the TB infection pressure in the community.
The rapidity with which risk increases following HIV
seroconversion is striking, rising 2-3-fold within the first 2
years of infection even prior to substantial depletion of the
blood CD4 cell count [28, 29]. In a primate of model of TB
and simian immunodeficiency virus (SIV) coinfection, risk
of reactivation TB was associated with the degree of initial
CD4 T cell depletion during the acute phase of SIV infection
[30]. It is possible that the acute phase of retroviral infection
is responsible for a shift in the host-pathogen relationship,
perhaps via deletion of critical T cell phenotypes that sets
up the path to inevitable TB reactivation at some stage
[31].
In addition to the early impact of HIV seroconversion
on immune containment of M. tuberculosis, the risk of TB
disease continues to rise as CD4 cell counts decrease [32–35].
In an Italian cohort, for example, TB incidence rates among
groups of antiretroviral treatment-(ART-) naı¨ve patients
with CD4 cell counts of >350, 200−350 and <200 cells/µL
were 0.5, 1.8, and 4.7 cases per 100 person-years, respectively
[35]. Rates among corresponding groups of patients in
South Africa were much higher at 3.6, 12.0, and 17.5
cases/100 person-years, respectively [32], probably reflecting
the extremely high rates of infection and ongoing re-
exposure to TB in the community [36].
4.3. Clinical Observations and Postmortem Studies. It is well
established that HIV infection has a profound impact on the
spectrum of TB disease, with progressive immunodeficiency
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being associated with an increased risk of extrapulmonary
and disseminated disease [37, 38]. Impairment of the host
inflammatory response is associated with much lower rates
of cavitation in the lung [39, 40], which in turn accounts for
more frequent sputum smear-negative disease and prolonged
time to positivity of automated liquid culture of sputum
[41, 42]. Despite lower bacillary burden in sputum, how-
ever, mycobacterial blood cultures, fine needle aspiration
of lymph nodes, and urinary antigen detection provide
evidence that the total numbers of mycobacteria in patients
with advanced HIV and TB may be very high [38, 42–
44].
Postmortem studies of HIV-infected patients conducted
in West, East, and Southern Africa also have remarkably
consistent findings. Each study found TB to be the common-
est cause of death [45–48], being present in over one third
of cadavers of HIV-infected patients who died in hospital
and in approximately one half of those with AIDS-defining
pathology [45–48]. In most cases, disease was dissemi-
nated. These data strongly suggest that disseminated HIV-
associated TB frequently remains clinically unsuspected and
undiagnosed and is a major contributor to HIV-associated
mortality in the region. In light of these observations, the
WHO estimate of approximately 0.5 million deaths per
year in patients with HIV-associated TB [2] may be an
underestimate.
4.4. “Unmasking” TB during Antiretroviral Treatment.
Observational studies of HIV-infected patients initiating
ART provide further evidence for the existence of subclinical
forms of active TB. In such patients, initiation of ART
appears to trigger the presentation of TB during the initial
weeks of therapy [49–51]. This phenomenon (often referred
to as “unmasking TB”) is thought to be mediated by rapid
restoration of M. tuberculosis-specific immune responses
[52]. In a South African cohort, this phenomenon was
estimated to account for approximately 40% of incident
TB cases in the first 4 months of ART [53] and this risk
was substantially reduced with use of intensive pre-ART TB
screening [54]. These data are consistent with the existence
of a spectrum of subclinical and clinical TB, the presentation
of which may be modified during rapid changes in immune
function mediated by ART.
4.5. Intensified Case Finding Studies. A meta-analysis of
intensified TB case finding studies (n = 12) from Africa
and Asia found that approximately one fifth of patients with
culture-proven HIV-associated TB were free of suggestive
symptoms and this proportion was broadly similar across
a range of CD4 cell counts [55]. Similarly a systematic
review of studies of intensified case finding for HIV-
associated TB found that routine microbiological screening
without prior patient selection using symptom screening
resulted in the identification of additional 4 cases of TB
for each 100 patients screened [56]. Thus, prevalence
rates of asymptomatic active TB among HIV-infected indi-
viduals in high TB burden settings can be considerable
[57].
5. Implications for Control of
HIV-Associated TB
Changing the paradigm of HIV-associated TB into one that
encompasses a spectrum of subclinical and symptomatic
disease has important potential implications for screening,
diagnosis, and prevention using isoniazid preventive therapy
and ART.
In the worst aﬀected region, the burden of HIV-
associated TB is often far greater than is clinically suspected
and this mandates having a low threshold for investigating
patients for TB. A major step forward is the development by
the World Health Organization and the Centers for Disease
Control and Prevention of a high sensitivity symptom
screening tool for use in HIV-infected patients [55]. In
contrast to the existing strategy of screening for cough of
2-3 weeks duration, this new screening tool identifies any
HIV-infected patient with cough (any duration), fever, night
sweats, or weight loss, and such patients should be further
evaluated for TB disease. Alternatively, in patient groups
with the highest risk, routine microbiological screening for
TB may be justified [54]. Such approaches should reduce
the prevalence of undiagnosed TB, potentially reducing
mortality and risk of TB transmission both in health care
settings [58] and in the community.
Novel high sensitivity assays are needed for diagnosis
of TB and active infection. Much of the developing world
remains reliant upon sputum smear microscopy which, in
those patient groups with the most advanced immunod-
eficiency, may have a sensitivity as low as 20% [42, 59].
Expanded availability of culture-based diagnosis is greatly
needed, and the development of rapid, simple, and accurate
diagnostic tools that can function as point-of-care tests
remains an essential goal. In those with most advanced
immunodeficiency, development of a point of care assay
that detects lipoarabinomannan (LAM) in urine may prove
to have some practical utility [42, 43]. However, simplified
forms of newer generations of nucleic acid amplification tests
have far greater sensitivity and are likely to represent a major
step forward [60–62].
New tools are also needed that are able to more precisely
define the spectrum of infection and disease states. Such
assays might provide prognostic information that indicate
the probability of progression of infection to TB disease
and also be used to monitor the response of disease
to treatment and assess the probability of relapse. With
these goals, considerable research eﬀorts are being made to
identify predictive biomarkers, which could be either host or
pathogen specific [63–65]. Development of such biomarkers
could also play a crucial role in expediting the development
and evaluation of new vaccines and drugs.
We have highlighted how disseminated TB frequently
remains undiagnosed in patients dying with HIV/AIDS in
sub-Saharan Africa. Existing WHO algorithms recommend
that seriously ill HIV-infected patients who have cough for 2-
3 weeks, are sputum smear-negative, and have not responded
to parenteral antibiotics (or treatment of Pneumocystis
jirovecii pneumonia where appropriate) are recommended
to be started on empiric TB treatment [66]. However, in
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the highest burden settings, a subgroup of HIV-infected
patients with advanced immunodeficiency have such a high
risk of TB and of associated mortality that they might
derive benefit from immediate initiation of empiric TB
treatment. Studies exploring such a strategy are needed
and one is being planned by the AIDS Clinical Trials
Group (ACTG5274 REMEMBER trial) (Mina Hosseinipour,
personal communication).
Despite WHO policy recommendations published in
1998 [67], only 0.1% of eligible HIV-infected individuals
received IPT in 2007 [68]. One key hindrance to more
widespread adoption of this intervention is the diﬃculty
of excluding active TB in HIV-infected individuals with
low CD4 cell counts [69]. Since the prevalence of culture-
proven active infection and TB disease rises steeply with
falling CD4 cell counts, the negative predictive value of
screening algorithms is significantly diminished in patient
groups with low CD4 cell counts [70]. In patient groups
such as those enrolling in ART services in which TB disease
prevalence exceeds 10% [56], there is therefore a well-
founded reluctance to start such patients on preventive
therapy using isoniazid monotherapy despite the lack of
objective evidence of an increased risk of generating isoniazid
resistant strains of M. tuberculosis [71]. Many such patients
require ART as the primary intervention anyway and this
functions as the key TB preventive intervention [70].
ART is associated with a 67% reduction (range: 54−92%)
in TB incidence [70, 72] due to CD4 cell count recovery
and restoration of functional anti-mycobacterial immune
responses [73–77]. Time-dependent reductions in TB risk
[78, 79] are very strongly related to changing absolute CD4
cell counts, with an almost 10-fold diﬀerence in adjusted
rates comparing patients with counts <100 cells/µL and
>500 cells/µL [53]. In those with pulmonary TB disease,
ART enhances organism clearance from sputum during TB
treatment but the clinical course may also be complicated by
immune reconstitution disease [50, 80].
In those with active infection, we hypothesize that ART
may have two alternative eﬀects. In those with the highest
organism load, ART may trigger “unmasking TB” [52].
Alternatively, by enhancing immune-mediated control, ART
may cause a shift in the host-pathogen relationship to restore
quiescent infection (Figure 1, Table 2). However, during
long-term ART, there is no evidence to suggest that complete
clearance of infection occurs. Those with optimum CD4
cell count recovery have persistently heightened TB risk that
remains several fold higher than background rates [53, 79].
In light of this, concurrent use of IPT during long-term
ART would be a logical approach in which complementary
immune-mediated and anti-mycobacterial mechanisms were
employed to reduce mycobacterial burden [70]. Data from
Brazil and Botswana support this suggestion [81, 82].
6. Conclusions
The traditional view of binary compartmentalised states
of latent TB infection and clinical TB disease is widely
acknowledged to be limited and yet this simple paradigmwas
broadly adequate for designing TB control interventions in
the pre-HIV era. However, although these conventional TB
control strategies have been associated with reductions in TB
rates in much of the world, this is not the case in regions with
high HIV prevalence. Here, additional interventions and new
tools are desperately required. Understanding “latent TB
infection” as a spectrum of immune responses, mycobacterial
metabolic activity and organism load redefines approaches to
screening, diagnosis and prevention of TB in HIV-infected
people. This also redefines the goals for the development of
new vaccines and for biomarker discovery and emphasizes
the pivotal role of ART in regaining immune control of active
infection.
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